Speeding Up the Evaluation of New Agents in Cancer

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2008 Aug 30

PMID 18728279

Citations 62

Authors

Mahesh K B Parmar

Friederike M-S Barthel

Matthew Sydes

Ruth Langley

Rick Kaplan

Elizabeth Eisenhauer

Mark Brady

Nicholas James

Michael A Bookman

Ann-Marie Swart

Wendi Qian

Patrick Royston

Affiliations

Soon will be listed here.

Abstract

Despite both the increase in basic biologic knowledge and the fact that many new agents have reached various stages of development during the last 10 years, the number of new treatments that have been approved for patients has not increased as expected. We propose the multi-arm, multi-stage trial design as a way to evaluate treatments faster and more efficiently than current standard trial designs. By using intermediate outcomes and testing a number of new agents (and combinations) simultaneously, the new design requires fewer patients. Three trials using this methodology are presented.

Citing Articles

Translational Challenges and Prospective Solutions in the Implementation of Biomimetic Delivery Systems.

Wang Z, Wang X, Xu W, Li Y, Lai R, Qiu X Pharmaceutics. 2023; 15(11).

PMID: 38004601 PMC: 10674763. DOI: 10.3390/pharmaceutics15112623.

Surrogacy validation for time-to-event outcomes with illness-death frailty models.

Roberts E, Elliott M, Taylor J Biom J. 2023; 66(1):e2200324.

PMID: 37776057 PMC: 10873101. DOI: 10.1002/bimj.202200324.

Adaptive experimental design produces superior and more efficient estimates of predator functional response.

Papanikolaou N, Moffat H, Fantinou A, Perdikis D, Bode M, Drovandi C PLoS One. 2023; 18(7):e0288445.

PMID: 37471391 PMC: 10358903. DOI: 10.1371/journal.pone.0288445.

Statistical analysis plan for the motor neuron disease systematic multi-arm adaptive randomised trial (MND-SMART).

Parker R, Weir C, Pham T, White I, Stallard N, Parmar M Trials. 2023; 24(1):29.

PMID: 36647114 PMC: 9843918. DOI: 10.1186/s13063-022-07007-z.

Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional Trials.

Park J, Sharif B, Harari O, Dron L, Heath A, Meade M JAMA Netw Open. 2022; 5(7):e2221140.

PMID: 35819785 PMC: 9277502. DOI: 10.1001/jamanetworkopen.2022.21140.

References

Bryant P, Venter D, Robins-Browne R, Curtis N . Chips with everything: DNA microarrays in infectious diseases. Lancet Infect Dis. 2004; 4(2):100-11. DOI: 10.1016/S1473-3099(04)00930-2. View

Royston P, Parmar M, Qian W . Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat Med. 2003; 22(14):2239-56. DOI: 10.1002/sim.1430. View

Herbst R, Giaccone G, Schiller J, Natale R, Miller V, Manegold C . Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004; 22(5):785-94. DOI: 10.1200/JCO.2004.07.215. View

DiMasi J, Hansen R, Grabowski H . The price of innovation: new estimates of drug development costs. J Health Econ. 2003; 22(2):151-85. DOI: 10.1016/S0167-6296(02)00126-1. View

Giaccone G, Herbst R, Manegold C, Scagliotti G, Rosell R, Miller V . Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004; 22(5):777-84. DOI: 10.1200/JCO.2004.08.001. View

Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R . Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26(12):2013-9. DOI: 10.1200/JCO.2007.14.9930. View

BAILAR 3rd J, Gornik H . Cancer undefeated. N Engl J Med. 1997; 336(22):1569-74. DOI: 10.1056/NEJM199705293362206. View

Bookman M, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs J . Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998; 16(10):3345-52. DOI: 10.1200/JCO.1998.16.10.3345. View

Simon R, Thall P, Ellenberg S . New designs for the selection of treatments to be tested in randomized clinical trials. Stat Med. 1994; 13(5-7):417-29. DOI: 10.1002/sim.4780130506. View

10.

Kris M, Natale R, Herbst R, Lynch Jr T, Prager D, Belani C . Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290(16):2149-58. DOI: 10.1001/jama.290.16.2149. View

11.

Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A . Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ. 2005; 331(7528):1295. PMC: 1298846. DOI: 10.1136/bmj.38628.561123.7C. View

12.

Mutabingwa T, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C . Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet. 2005; 365(9469):1474-80. DOI: 10.1016/S0140-6736(05)66417-3. View

13.

Kola I, Landis J . Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov. 2004; 3(8):711-5. DOI: 10.1038/nrd1470. View

14.

Lane D . The promise of molecular oncology. Lancet. 1998; 351 Suppl 2:SII17-20. DOI: 10.1016/s0140-6736(98)90328-2. View

15.

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J . Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003; 21(12):2237-46. DOI: 10.1200/JCO.2003.10.038. View

16.

Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P . Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21(14):2636-44. DOI: 10.1200/JCO.2003.11.136. View

17.

Roberts Jr T, Lynch Jr T, Chabner B . The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. J Clin Oncol. 2003; 21(19):3683-95. DOI: 10.1200/JCO.2003.01.204. View

18.

Schmidli H, Bretz F, Racine A, Maurer W . Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations. Biom J. 2006; 48(4):635-43. DOI: 10.1002/bimj.200510231. View

19.

Buyse M, Molenberghs G . Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics. 1998; 54(3):1014-29. View

20.

. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet. 2002; 359(9308):733-40. DOI: 10.1016/S0140-6736(02)07874-1. View